arri buy beacon hit os interim
like new standard braf
reiter buy pt
messag arri report posit interim result on-going beacon
trial braf colorect cancer trial hit object respons rate orr
overal surviv os endpoint consist bull-cas highlight
recent deep dive base prior work kol think arri braftovi/
mektovi combo becom new standard care braf expect rapid
commerci uptak potl immedi posit impact product sale driven off-
label use ahead approv reiter buy increas pt
posit beacon interim readout respons rate overal surviv
consist thesi see deep dive result includ orr first
random patient triplet regimen doublet
control arm interim os analysi februari data cutoff includ month
triplet month doublet month control arm orr
patient higher includ triplet doublet regimen
respect per management comment call full result come potenti esmo
world gi confer juli orr came investor expect os
repres signific posit surpris remain question pertain median
median durat therapi
uncompetit field without approv therapi orr mo decreas
rel safeti lead-in result month respect compani
beacon princip investig well braf kol note emphas
practice-chang potenti triplet even efficaci data decreas safeti
lead-in compani highlight complet lack currently-approv therapi
also potenti competitor regimen near futur combin braftovi/
mektovi melanoma opportun front-lin braf believ us sale
could exceed near term estim may conserv given
also assum low triplet regimen uptak among patient braf
msi-h
beacon readout read-through posit front-lin anchor
trial recal anchor evalu beacon triplet front-lin braf
patient enrol sinc earli posit beacon readout
view de-risk anchor trial could potenti drive increas off-label
util front-lin prior offici approv indic
adjust estim base posit trial outcom maintain buy increas
pt light posit interim analysi arri reiter guidanc toward
regulatori submiss increas model po braf
pt prior
page analyst certif import disclosur
valuat risk
valu array biopharma arri per share use dcf base valuat method
valuat includ commerci product braftovi mektovi well probability-
adjust cash flow deriv compani pipelin out-licens program use
discount rate termin growth rate appli termin year post-assum
gener entri increas probabl success estim indic
risk valuat array biopharma includ regulatori commerci setback
potenti emerg new competitor lower product sale expect
page analyst certif import disclosur
arri mm
licens mileston revenu
arri bs cf mm
guggenheim secur llc estim sec file
page analyst certif import disclosur
